OncoMatch/Clinical Trials/NCT06876662
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Is NCT06876662 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Pirtobrutinib for chronic lymphocytic leukemia.
Treatment: Pirtobrutinib — Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sylvester Comprehensive Cancer Center · Miami, Florida
- Florida Cancer Specialists · Sarasota, Florida
- The Emory Clinic · Atlanta, Georgia
- Northwestern University · Chicago, Illinois
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06876662 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify